Tue, Nov 05, 2024 08:15 CET Report this content Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria …
ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe
Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria vaccine. BioStock talked to CEO Bent U. Frandsen about this at the partnering conference BIO-Europe.
See the full interview at biostock.se:
https://www.biostock.se/2024/11/expres2ion-ceo-talking-about-partnering-efforts-at-bio-europe/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
